Can a radioactive tracer pinpoint Cancer's first stop?

NCT ID NCT07764653

First seen Aug 14, 2026 ยท Last updated Aug 14, 2026

Summary

This trial is testing whether a radioactive tracer, technetium Tc 99m sulfur colloid, can accurately locate sentinel lymph nodes in women with early-stage breast cancer. The sentinel node is the first lymph node cancer is likely to spread to, and finding it helps guide surgery. The study compares this tracer to a standard blue dye to see which is better at detecting these nodes, and also checks for safety and consistency between the two methods.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Technetium Tc 99m Sulfur Colloid Injection (a radioactive tracer)
What this could lead to
If successful, this could offer a more accurate and safer way to locate sentinel lymph nodes during breast cancer surgery, potentially reducing the need for more invasive lymph node removal.
What could go wrong
This is a phase 3 trial, but results are not yet available. The tracer may not be as effective as the standard dye in all patients, and there is a small risk of radiation exposure or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.